Strabismus and Amblyopia Digital Therapeutics Market Report 2026

The strabismus and amblyopia digital therapeutics market size has grown rapidly in recent years. It will grow from $0.61 billion in 2025 to $0.68 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to rising pediatric vision disorders, limited access to specialists, early diagnosis programs, traditional patching limitations, school vision screening.

The strabismus and amblyopia digital therapeutics market size is expected to see rapid growth in the next few years. It will grow to $1.02 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to increased smartphone penetration, reimbursement for digital therapeutics, ai-powered vision analytics, rising screen exposure concerns, global pediatric healthcare investment. Major trends in the forecast period include gamified vision therapy, mobile-based eye exercises, AI-driven vision tracking, remote patient monitoring, home-based treatment models.

The expansion of telehealth is expected to drive growth in the strabismus and amblyopia digital therapeutics market in the coming years. Telehealth involves using digital communication technologies to deliver healthcare services, consultations, and monitoring remotely between patients and healthcare providers. Its growth is fueled by increased access to care, allowing patients, particularly in remote or underserved areas, to consult specialists and receive treatment without traveling or attending in-person visits. Telehealth supports strabismus and amblyopia digital therapeutics by enabling continuous remote monitoring and guidance, allowing patients - especially children - to undergo consistent and supervised therapy from home. For example, in September 2024, the Australian Bureau of Statistics (ABS), the national statistical agency of Australia, reported that in 2023-24, 83.5% of males used telehealth services, up from 78.6% in 2022-23. Therefore, the growth of telehealth is driving the expansion of the strabismus and amblyopia digital therapeutics market.

Key companies in the strabismus and amblyopia digital therapeutics market are focusing on technological innovations, such as binocular virtual-reality amblyopia treatment platforms, to deliver engaging and effective vision therapy to older children for whom traditional treatments may be less effective. A binocular virtual-reality amblyopia treatment platform is a prescription medical device that uses VR and modified visual content to stimulate both eyes simultaneously, improving binocular vision rather than penalizing the stronger eye. For instance, in April 2025, Luminopia, Inc., a US-based provider of digital therapeutics for neuro-visual disorders, received FDA clearance for its Luminopia One system for children aged 8 to 12 years, expanding its prior indication for ages 4-7. The system uses immersive VR headsets where patients watch popular TV shows six days a week while software algorithms apply contrast reduction and dichoptic masking to encourage use of the amblyopic eye. It supports home-based treatment to improve compliance and is backed by a large real-world evidence registry showing vision improvements even in previously treated patients.

In March 2025, Pentec Health Inc., a US-based healthcare company, partnered with Luminopia Inc. to provide support and distribution services aimed at expanding Luminopia’s market reach. This partnership aligns with Pentec’s mission to deliver trusted care solutions for patients with complex needs and supports Luminopia’s goal of making treatments widely accessible. Luminopia Inc., based in the US, specializes in digital therapeutics for amblyopia and mild strabismus.

Major companies operating in the strabismus and amblyopia digital therapeutics market are Ocutrx Vision Technologies LLC, Orthoptics Australia Inc., Good-Lite Company, AmblyoPlay, NovaSight Ltd., Luminopia Inc., NeuraSim Health, Bynocs Inc., RevitalVision LLC, Vivid Vision Inc., Binovi Technologies Corp., Wow Vision Therapy, OculoMotor Technologies Inc., Web Vision Therapy, CureSee Vision Therapy, AnteoTech Ltd, VisionBuilder, HTS Vision Therapy Systems, Visionary Therapeutics Inc., NeuroVision Therapy Solutions.

North America was the largest region in the strabismus and amblyopia digital therapeutics market in 2025. The regions covered in the strabismus and amblyopia digital therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the strabismus and amblyopia digital therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the strabismus and amblyopia digital therapeutics market by raising the cost of imported VR headsets, eye-tracking devices, sensors, and digital hardware. Ophthalmic clinics and hospitals in Asia-Pacific and Europe are most impacted due to reliance on international technology suppliers. These higher costs can slow adoption of hardware-based digital therapies. However, tariffs are encouraging local software development and device assembly, strengthening long-term market growth.

The strabismus and amblyopia digital therapeutics market research report is one of a series of new reports that provides strabismus and amblyopia digital therapeutics market statistics, including strabismus and amblyopia digital therapeutics industry global market size, regional shares, competitors with a strabismus and amblyopia digital therapeutics market share, detailed strabismus and amblyopia digital therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the strabismus and amblyopia digital therapeutics industry. This strabismus and amblyopia digital therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Strabismus and amblyopia digital therapeutics are software-based medical interventions developed to treat visual misalignment and impaired vision through interactive, technology-driven platforms. These therapies are often customized to the individual’s needs and progress, supporting visual improvement through regular engagement and remote monitoring.

The main types of strabismus and amblyopia digital therapeutics include software and hardware. Software-based digital therapeutics consist of applications designed to address eye conditions such as strabismus and amblyopia. They are used for treating strabismus (crossed eyes) and amblyopia (lazy eye) and are applied in settings such as hospitals, ophthalmic clinics, and others.

The strabismus and amblyopia digital therapeutics market consists of revenues earned by entities by providing services such as digital vision therapy programs, remote patient monitoring, gamified therapeutic exercises, teleconsultation and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The strabismus and amblyopia digital therapeutics market also includes sales of tablet-based therapy kits, eye-tracking devices, therapy management dashboards and vision assessment tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.